Analisi di costo-utilità di ceftolozano/tazobactam rispetto a meropenem in pazienti con polmonite acquisita in ospedale (HABP) o polmonite associata a ventilazione meccanica (VABP).

Mennini, Francesco Saverio; Paoletti, Martina; Bini, Chiara; Marcellusi, Andrea; Falcone, Marco; Andreoni, Massimo

Mennini, Francesco Saverio; Paoletti, Martina; Bini, Chiara; Marcellusi, Andrea; Falcone, Marco; Andreoni, Massimo.

Afiliación

Mennini FS; Faculty of Economics, Economic Evaluation and HTA (EEHTA), CEIS, University of Rome "Tor Vergata", Rome - Italy.
Paoletti M; Institute for Leadership and Management in Health - Kingston University London, London - UK.
Bini C; Faculty of Economics, Economic Evaluation and HTA (EEHTA), CEIS, University of Rome "Tor Vergata", Rome - Italy.
Marcellusi A; Faculty of Economics, Economic Evaluation and HTA (EEHTA), CEIS, University of Rome "Tor Vergata", Rome - Italy.
Falcone M; Faculty of Economics, Economic Evaluation and HTA (EEHTA), CEIS, University of Rome "Tor Vergata", Rome - Italy.
Andreoni M; Institute for Leadership and Management in Health - Kingston University London, London - UK.

Glob Reg Health Technol Assess ; 9: 45-57, 2022.

Article en It | MEDLINE | ID: mdl-36628307

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Tipo de estudio: Risk_factors_studies Idioma: It Revista: Glob Reg Health Technol Assess Año: 2022 Tipo del documento: Article

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google